Ki67 is a promising molecular target in the diagnosis of cancer (Review)

Li,Lian  Tao; Jiang,Guan; Chen,Qian; Zheng,Jun  Nian

doi:10.3892/mmr.2014.2914

Ki67 is a promising molecular target in the diagnosis of cancer (Review)

Authors:
- Lian Tao Li
- Guan Jiang
- Qian Chen
- Jun Nian Zheng
View Affiliations

Affiliations: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/mmr.2014.2914
Pages: 1566-1572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of Ki67 is strongly associated with tumor cell proliferation and growth, and is widely used in routine pathological investigation as a proliferation marker. The nuclear protein Ki67 (pKi67) is an established prognostic and predictive indicator for the assessment of biopsies from patients with cancer. Clinically, pKi67 has been shown to correlate with metastasis and the clinical stage of tumors. In addition, it has been shown that Ki67 expression is significantly higher malignant tissues with poorly differentiated tumor cells, as compared with normal tissue. According to its predictive role, pKi67 expression identifies subpopulations of patients who are more likely to respond to a given therapy. The Ki67 labeling index is an independent prognostic factor for survival rate, which includes all stages and grade categories. There is a correlation between the ratio of Ki67‑positive malignant cells and patient survival. It has been shown that blocking of Ki67 either by microinjection of antibodies or through the use of antisense oligonucleotides leads to the arrest of cell proliferation. Specifically, antisense oligonucleotides and antibodies against pKi67 have been shown to inhibit the progression of the cell cycle. The Ki67 protein is well characterized at the molecular level and is extensively used as a prognostic and predictive marker for cancer diagnosis and treatment. Increasing evidence indicates that Ki67 may be an effective target in cancer therapy. It therefore merits further development, including testing in more sophisticated in vitro and appropriate in vivo models. This review provides an overview of recent advances in this field.

View Figures

View References

1	Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
2	Shirendeb U, Hishikawa Y, Moriyama S, et al: Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem. 42:181–190. 2009. View Article : Google Scholar
3	Hooghe B, Hulpiau P, Van Roy F and De Bleser PD: ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res. 36:W128–W132. 2008. View Article : Google Scholar : PubMed/NCBI
4	Modlin IM, Moss SF, Chung DC, et al: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 100:1282–1289. 2008. View Article : Google Scholar : PubMed/NCBI
5	Klöppel G, Perren A and Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 1014:13–27. 2004. View Article : Google Scholar : PubMed/NCBI
6	Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ishihara M, Mukai H, Nagai S, et al: Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Oncology. 84:135–140. 2013. View Article : Google Scholar
8	Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One. 7:e470682012. View Article : Google Scholar : PubMed/NCBI
9	Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol. 12:72012. View Article : Google Scholar : PubMed/NCBI
10	Ciancio N, Galasso MG, Campisi R, et al: Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med. 7:292012. View Article : Google Scholar : PubMed/NCBI
11	Josefsson A, Wikström P, Egevad L, et al: Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol. 46:247–257. 2012. View Article : Google Scholar : PubMed/NCBI
12	Iatropoulos MJ and Williams GM: Proliferation markers. Exp Toxicol Pathol. 48:175–181. 1996. View Article : Google Scholar : PubMed/NCBI
13	Jacquemier JD, Penault-Llorca FM, Bertucci F, et al: Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol. 184:130–135. 1998. View Article : Google Scholar : PubMed/NCBI
14	Kausch I, Lingnau A, Endl E, et al: Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer. 105:710–716. 2003. View Article : Google Scholar : PubMed/NCBI
15	Liu J, Fang L, Cheng Q, et al: Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell. Cancer Sci. 103:1880–1888. 2012. View Article : Google Scholar : PubMed/NCBI
16	Gerlach C, Sakkab DY, Scholzen T, et al: Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology. 26:573–578. 1997. View Article : Google Scholar : PubMed/NCBI
17	Le Guellec S, Perallon R, Alunni JP, et al: Neoadjuvant treatment of breast cancer: implications for the pathologist. Ann Pathol. 31:442–454. 2011.(In French). View Article : Google Scholar : PubMed/NCBI
18	Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
19	Duchrow M, Schlüter C, Wohlenberg C, et al: Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 29:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
20	Halm U, Tannapfel A, Breitung B, et al: Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett’s esophagus. Hepatogastroenterology. 47:962–966. 2000.PubMed/NCBI
21	Rahmanzadeh R, Hüttmann G, Gerdes J and Sholzen T: Chromophore-assisted light inactivation of pKi67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. 40:422–430. 2007. View Article : Google Scholar : PubMed/NCBI
22	Castro LA, Elias LS, Oton-Leite AF, et al: Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci. 52:55–62. 2010. View Article : Google Scholar : PubMed/NCBI
23	Panteva MT, Salari R, Bhattacharjee M and Chong LT: Direct observations of shifts in the β-sheet register of a protein-peptide complex using explicit solvent simulations. Biophys J. 100:L50–L52. 2011. View Article : Google Scholar : PubMed/NCBI
24	Tian H, Qian GW, Li W, et al: A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumour Biol. 32:273–283. 2011. View Article : Google Scholar
25	Chen F, Song J, Di J, et al: IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation. Tumour Biol. 33:2217–2225. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nakano T, Ohno T, Ishikawa H, et al: Current advancement in radiation therapy for uterine cervical cancer. J Radiat Res. 51:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kim BH, Bae YS, Kim SH, et al: Usefulness of Ki-67 (MIB-1) immunostaining in the diagnosis of pulmonary sclerosing hemangiomas. APMIS. 121:105–110. 2013. View Article : Google Scholar
28	Steels E, Paesmans M, Berghmans T, et al: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
29	Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 91:2018–2025. 2004. View Article : Google Scholar : PubMed/NCBI
30	Faes T, Pecceu A, Van Calenbergh S and Moerman P: Chorangiocarcinoma of the placenta: a case report and clinical review. Placenta. 33:658–661. 2012. View Article : Google Scholar : PubMed/NCBI
31	Almeida JC, Menezes RP, Kuckelhaus SA, Bocca AL and Figueiredo F: Prognostic value of morphologic and clinical parameters in pT2 – pT3 prostate cancer. Int Braz J Urol. 33:662–672. 2007. View Article : Google Scholar : PubMed/NCBI
32	Vaira V, Fedele G, Pyne S, et al: Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA. 107:8352–8356. 2010. View Article : Google Scholar : PubMed/NCBI
33	Hofman MS and Hicks RJ: Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 14:71–81. 2012.PubMed/NCBI
34	Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al: A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 16:R352014. View Article : Google Scholar : PubMed/NCBI
35	Hayashi Y, Takei H and Kurosumi M: Ki67 immunohistochemical staining: the present situation of diagnostic criteria. Nihon Rinsho. 7:428–432. 2012.(In Japanese).
36	Zizi-Sermpetzoglou A, Moustou E, Petrakopoulou N, et al: Atypical polypoid adenomyoma of the uterus. A case report and a review of the literature. Eur J Gynaecol Oncol. 33:118–121. 2012.PubMed/NCBI
37	Zini L, Porpiglia F and Fassnacht M: Contemporary management of adrenocortical carcinoma. Eur Urol. 60:1055–1065. 2011. View Article : Google Scholar : PubMed/NCBI
38	Viale G: Pathological work up of the primary tumor: getting the proper information out of it. Breast. 20(Suppl 3): S82–S86. 2011. View Article : Google Scholar : PubMed/NCBI
39	Leong AS and Zhuang Z: The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 78:99–114. 2011. View Article : Google Scholar : PubMed/NCBI
40	Ibrahim T, Farolfi A, Scarpi E, et al: Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical impact. Oncology. 84:150–157. 2013. View Article : Google Scholar
41	Chlebowski RT, Col N, Winer EP, et al; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 20:3328–3343. 2002. View Article : Google Scholar : PubMed/NCBI
42	Blancato J, Singh B, Liu A, Liao DJ and Dickson RB: Correlation of amplification and overexpression of the c-myc oncogene in high grade breast cancer: FISH, in situ hybridization and immunohistochemical analysis. Br J Cancer. 90:1612–1619. 2004. View Article : Google Scholar : PubMed/NCBI
43	Jonat W and Arnold N: Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 22:500–502. 2011. View Article : Google Scholar : PubMed/NCBI
44	Sapino A, Marchiò C, Senetta R, et al: Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 449:288–296. 2006. View Article : Google Scholar : PubMed/NCBI
45	Camp RL, Neumeister V and Rimm DL: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 26:5630–5637. 2008. View Article : Google Scholar : PubMed/NCBI
46	Konsti J, Lundin M, Joensuu H, et al: Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol. 11:32011. View Article : Google Scholar : PubMed/NCBI
47	Klimowicz AC, Bose P, Nakoneshny SC, et al: Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. Eur J Cancer. 48:2166–2174. 2012. View Article : Google Scholar : PubMed/NCBI
48	Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, et al: Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques. 48:389–397. 2010. View Article : Google Scholar : PubMed/NCBI
49	Farragher SM, Tanney A, Kennedy RD and Paul Harkin D: RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol. 130:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
50	Mittempergher L, de Ronde JJ, Nieuwland M, et al: Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One. 6:e171632011. View Article : Google Scholar : PubMed/NCBI
51	Karamitopoulou E, Perentes E, Tolnay M and Probst A: Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol. 29:140–145. 1998. View Article : Google Scholar : PubMed/NCBI
52	Geyer FC, Rodrigues DN, Weigelt B and Reis-Filho JS: Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 19:39–53. 2012. View Article : Google Scholar
53	Claudio PP, Zamparelli A, Garcia FU, et al: Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma1. Clin Cancer. 8:1808–15. 2002.
54	Hu HY, Liu H, Zhang JW, et al: Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepato-gastroenterology. 59:2640–2643. 2012.PubMed/NCBI
55	McCormick D, Chong H, Hobbs C, et al: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology. 22:355–360. 1993. View Article : Google Scholar : PubMed/NCBI
56	Merkel D, Dresseler L and McGuire WL: Flow cytometry, cellular DNAcontent, and prognosis in human malignancy. J Clin Oncol. 5:1690–1703. 1987.PubMed/NCBI
57	Clark GM, Mathieu M-C, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol. 10:428–432. 1992.PubMed/NCBI
58	Fernandez EB, Sesterhenn IA, McCarthy WF, et al: Proliferating cellnuclear antigen expression to predict occult disease in clinical stage Inonseminomatous testicular germ cell tumors. J Urol. 152:1133–1138. 1994.PubMed/NCBI
59	de Aguiar PH, Aires R, Laws ER, et al: Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role?. A critical review. Neurol Res. 32:1060–1071. 2010. View Article : Google Scholar : PubMed/NCBI
60	Prayson RA: The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol. 12:144–148. 2005. View Article : Google Scholar : PubMed/NCBI
61	Lind-Landström T, Habberstad AH, Sundstrøm S and Torp SH: Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 5:152–158. 2012.PubMed/NCBI
62	Nabi U, Nagi AH and Sami W: Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad. 20(4): 44–8. 2008.PubMed/NCBI
63	Hegazy A, Daoud SA and Ibrahim WS: Role of Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma. Academic Journal of Cancer Research. 7(3): 168–172. 2014.
64	Inwald EC, Klinkhammer-Schalke M and Hofstädter F: Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 139(2): 539–52. 2013. View Article : Google Scholar : PubMed/NCBI
65	Klöppel G, Perren A and Heiitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann NY Acad Sci. 1014:13–27. 2004. View Article : Google Scholar : PubMed/NCBI
66	Morimoto R, Satoh F, Murakami O, et al: Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 55:49–55. 2008. View Article : Google Scholar : PubMed/NCBI
67	Gupta N, Srinivasan R and Rajwanshi A: Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol. 38:618–623. 2010.
68	Jalava P, Kuopio T, Juntti-Patinen L, et al: Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 48:674–682. 2006. View Article : Google Scholar : PubMed/NCBI
69	Zhang B: Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer. Zhonghua Zhong Liu Za Zhi. 33:241–244. 2011.(In Chinese). PubMed/NCBI
70	Gentile V, Vicini P, Giacomelli L, et al: Detection of human papillomavirus DNA, p53 and ki-67 expression in penile carcinomas. Int J Immunopathol Pharmacol. 19:209–215. 2006.PubMed/NCBI
71	Kroeze SG, Bijenhof AM, Bosch JL and Jans JJ: Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark. 7:261–268. 2010.PubMed/NCBI
72	D’Angelo E and Prat J: Uterine sarcomas: a review. Gynecol Oncol. 116:131–139. 2010. View Article : Google Scholar
73	Yu JY, DeRuiter SL and Turner DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA. 99:6047–6052. 2002. View Article : Google Scholar : PubMed/NCBI
74	Li L, Thomas RM, Suzuki H, et al: A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 305:1471–1474. 2004. View Article : Google Scholar : PubMed/NCBI
75	Ben-Izhak O, Bar-Chana M, Sussman L, et al: Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology. 41:519–525. 2002. View Article : Google Scholar : PubMed/NCBI
76	Hu HY, Liu H, Zhang JW, et al: Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology. 59:2640–2643. 2012.PubMed/NCBI
77	Liu YZ, Jiang YY, Hao JJ, et al: Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 77:176–182. 2012. View Article : Google Scholar : PubMed/NCBI
78	Golmohammadi R and Pejhan A: The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc. 62:871–875. 2012.PubMed/NCBI
79	Tihan T, Davis R, Elowitz E, et al: Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med. 124:108–113. 2000.PubMed/NCBI
80	Iamaroon A, Khemaleelakul U, Pongsiriwet S and Pintong J: Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med. 33:30–36. 2004. View Article : Google Scholar
81	Boonyaphiphat P, Pruegsanusak K and Thongsuksai P: The prognostic value of p53, Bcl-2 and Bax expression in laryngeal cancer. J Med Assoc Thai. 95:1317–1320. 2012.PubMed/NCBI
82	Tadbir AA, Pardis S, Ashkavandi ZJ, et al: Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev. 13:5155–5159. 2012. View Article : Google Scholar : PubMed/NCBI
83	Chen JX, Deng N, Chen X, et al: A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev. 13:2229–2234. 2012. View Article : Google Scholar : PubMed/NCBI
84	Hoogerbrugge N, Hermens RP, Nagengast F, et al: Tumour examination to detect hereditary colorectal cancer. Ned Tijdschr Geneeskd. 156:A49822012.(In Dutch).
85	Nabi U, Nagi AH and Sami W: Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad. 20:44–48. 2008.PubMed/NCBI
86	Tvedskov TF: Staging of women with breast cancer after introduction of sentinel node guided axillary dissection. Dan Med J. 59:B44752012.PubMed/NCBI
87	Wang MJ, Pei DS, Qian GW, et al: p53 regulates Ki-67 promoter activity through p53-and Sp1-dependent manner in HeLa cells. Tumour Biol. 32:905–912. 2011. View Article : Google Scholar : PubMed/NCBI
88	Grala B, Markiewicz T, Kozowski W, et al: New automated image analysis method for the assessment of Ki-67 labeling index in meningiomas. Folia Histochem Cytobiol. 47:587–592. 2009.PubMed/NCBI
89	Tuominen VJ, Ruotoistenmäki S, Viitanen A, et al: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12:R562010. View Article : Google Scholar : PubMed/NCBI
90	Gilles FH, Tavaré CJ, Becker LE, et al: Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr Dev Pathol. 11:108–117. 2008. View Article : Google Scholar
91	Grzybicki DM, Liu Y, Moore SA, et al: Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer. 92:2720–2726. 2001. View Article : Google Scholar : PubMed/NCBI
92	Hsu CY, Ho DM, Yang CF and Chiang H: Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol. 16:951–957. 2003. View Article : Google Scholar : PubMed/NCBI
93	Walker RA: Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology. 49:406–410. 2006. View Article : Google Scholar : PubMed/NCBI
94	Bertucci F, Finetti P, Roche H, et al: Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Ann Oncol. 24:625–632. 2013. View Article : Google Scholar
95	Nielsen PS, Riber-Hansen R, Raundahl J and Steiniche T: Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. Arch Pathol Lab Med. 136:627–634. 2012. View Article : Google Scholar : PubMed/NCBI
96	Nielsen PS, Riber-Hansen R and Steiniche T: Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol. 33:361–370. 2011. View Article : Google Scholar : PubMed/NCBI
97	Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar : PubMed/NCBI
98	Chang J, Ormerod M, Powles TJ, et al: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 89:2145–2152. 2000. View Article : Google Scholar
99	Viale G, Giobbie-Hurder A, Regan MM, et al: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 26:5569–75. 2008. View Article : Google Scholar : PubMed/NCBI
100	Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
101	Park JY, Kim KR and Nam JH: Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma. Int J Gynecol Cancer. 23:81–89. 2013. View Article : Google Scholar
102	Nagao K, Yamamoto Y, Hara T, et al: Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml. Jpn J Clin Oncol. 41:555–564. 2011. View Article : Google Scholar : PubMed/NCBI
103	Machowska M, Wachowicz K, Sopel M, et al: Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer. 14:1422014. View Article : Google Scholar : PubMed/NCBI
104	Nielsen PS, Riber-Hansen R, Jensen TO, et al: Proliferation indices of phosphor-histone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol. 26(3): 404–13. 2013. View Article : Google Scholar
105	Vogt N and Klapper W: Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology. 62:334–342. 2013. View Article : Google Scholar
106	Palmqvist R, Sellberg P, Oberg A, et al: Low tumour cell proliferation at the invasive marginis associated with a poor prognosis in Dukes’ stage B colorectal cancers. Br J Cancer. 79:577–581. 1999. View Article : Google Scholar : PubMed/NCBI
107	Kimura T, Tanaka S, Haruma K, et al: Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 16:55–64. 2000.
108	Holdcraft J and Gallagher JC: Malignant melanomas of the nasal and paranasal sinus mucosa. Ann Otol Rhinol Laryngol. 78:5–20. 1969. View Article : Google Scholar : PubMed/NCBI
109	Rinaldo A, Shaha AR, Patel SG and Ferlito A: Primary mucosal melanoma of the nasal cavity and paranasal sinuses. Acta Otolaryngol. 121:979–982. 2001. View Article : Google Scholar
110	Bisgaard ML: Young age colorectal cancer and identification of hereditary non-polyposis colorectal cancer cohorts. Br J Surg. 94:1055–1056. 2007. View Article : Google Scholar : PubMed/NCBI
111	Niezabitowski A, Czajecki K, Ryś J, et al: Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol. 70:150–160. 1999. View Article : Google Scholar : PubMed/NCBI
112	Tuleta I, Bauriedel G, Steinmetz M, et al: Apoptosis-regulated survival of primarily extravascular cells in proliferative active poststent neointima. Cardiovasc Pathol. 19:353–360. 2010. View Article : Google Scholar
113	Wajed SA, Laird PW and DeMeester TR: DNA methylation: an alternative pathway to cancer. Ann Surg. 234:10–20. 2001. View Article : Google Scholar : PubMed/NCBI
114	Zheng JN, Ma TX, Cao JY, et al: Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci. 78:724–729. 2006. View Article : Google Scholar
115	Zheng JN, Sun YF, Pei DS, et al: Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci. 76:1873–1881. 2005. View Article : Google Scholar : PubMed/NCBI
116	Chan JH, Lim S and Wong WS: Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 33:533–540. 2006. View Article : Google Scholar : PubMed/NCBI
117	Paulasova P and Pellestor F: The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet. 47:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
118	Smolina IV and Demidov VV: Sequence-universal recognition of duplex DNA by oligonucleotides via pseudocomplementarity and helix invasion. Chem Biol. 10:591–595. 2003. View Article : Google Scholar : PubMed/NCBI
119	Demidov VV and Frank-Kamenetskii MD: Two sides of the coin: affinity and specificity of nucleic acid interactions. Trends Biochem Sci. 29:62–71. 2004. View Article : Google Scholar : PubMed/NCBI
120	Demidov VV, Potaman VN, Frank-Kamenetskii MD, et al: Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol. 48:1310–1313. 1994. View Article : Google Scholar : PubMed/NCBI
121	Tuschl T: RNA interference and small interfering RNAs. Chembiochem. 2:239–245. 2001. View Article : Google Scholar
122	Zheng JN, Pei DS, Mao LJ, et al: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 16:20–32. 2009. View Article : Google Scholar
123	Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF and Wu TC: Prospects of RNA interference therapy for cancer. Gene Ther. 13:464–477. 2006. View Article : Google Scholar
124	Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
125	Lieberman J, Song E, Lee SK and Shankar P: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med. 9:397–403. 2003. View Article : Google Scholar : PubMed/NCBI
126	Moore CB, Guthrie EH, Huang MT and Taxman DJ: Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 629:141–158. 2010.PubMed/NCBI
127	Zhu H, Guo W, Zhang L, et al: Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 4:451–456. 2005.PubMed/NCBI
128	Starborg M, Gell K, Brundell E and Höög C: The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci. 109:143–153. 1996.PubMed/NCBI
129	Zhang P, Steelant W, Kumar M and Scholfield M: Versatile photosensitizers for photodynamic therapy at infrared excitation. J Am Chem Soc. 129:4526–4527. 2007. View Article : Google Scholar : PubMed/NCBI